In Brief: Biocontrol Technology
This article was originally published in The Gray Sheet
Executive Summary
Biocontrol Technology: Pittsburgh, Pennsylvania-based firm announces Oct. 26 that its Diasense subsidiary has entered an agreement with Imaco Gesellschaft fur Non Invasive Systeme, GmbH for the German distribution of the Diasensor 1000 non-invasive glucose sensor. Imaco will pay $32.5 mil. for exclusive distribution rights to the product and will be required to purchase "a total of 5100 machines in 1996 at a rate of 100 for the first month and 500 a month for the next 10 months," Biocontrol says...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.